Combination cancer treatment
AssigneeWisconsin Alumni Research Foundation
InventorsVincent Leonard Cryns, Dmitry Malin, Elena Strekalova
Life of this patent
Estimating the term…
Abstract
Described herein is TRAIL receptor targeting therapy in combination with metformin for treatment of cancer in humans. Using TRAIL receptor targeting therapy such as the TRAIL molecule, agonistic human monoclonal antibodies against TRAIL receptors, or peptides targeting TRAIL receptors in combination with metformin for the treatment of all types of cancer allows to obtain an optimum therapeutical effect at any time of the progression of the disease.
Claims22
A method of treating cancer in a human individual in need of treatment for cancer, comprising co-administering metformin and a TRAIL receptor agonist, wherein the metformin is administered in an effective amount to sensitize cancer cells to the TRAIL receptor agonist.
A method of improving the sensitivity of a human cancer patient to TRAIL receptor agonist therapy, comprising
- identifying a human cancer patient as a candidate for TRAIL receptor agonist therapy,
- and administering to the patient both metformin and a TRAIL receptor agonist, wherein metformin is administered to the patient before, during, or after administration of the TRAIL receptor agonist, and wherein the metformin is administered in an effective amount to sensitize cancer cells to the TRAIL receptor agonist.
Dependencies are inferred from the claim text.